These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32848438)

  • 1. Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China.
    Men P; Liu T; Zhai S
    Diabetes Metab Syndr Obes; 2020; 13():2823-2831. PubMed ID: 32848438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.
    Huang K; Wang Y; Sun S; Zhu Q; Zhou W; Liu J; Zhu D; Xie X
    Front Public Health; 2022; 10():936703. PubMed ID: 35910934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective.
    Lin X; Lin M; Liu M; Huang W; Nie X; Chen Z; Zheng B
    J Thorac Dis; 2022 May; 14(5):1588-1597. PubMed ID: 35693603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
    Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
    Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
    Ramos M; Men P; Wang X; Ustyugova A; Lamotte M
    Cost Eff Resour Alloc; 2021 Aug; 19(1):46. PubMed ID: 34348729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
    Reifsnider OS; Kansal AR; Franke J; Lee J; George JT; Brueckmann M; Kaspers S; Brand SB; Ustyugova A; Linden S; Stargardter M; Hau N
    ESC Heart Fail; 2020 Dec; 7(6):3910-3918. PubMed ID: 32909680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
    Ramos M; Foos V; Ustyugova A; Hau N; Gandhi P; Lamotte M
    Diabetes Ther; 2019 Dec; 10(6):2153-2167. PubMed ID: 31602601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China.
    Jiang Y; Zheng R; Sang H
    Front Pharmacol; 2021; 12():733681. PubMed ID: 34858172
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
    Abushanab D; Liew D; Marquina C; Al-Badriyeh D; Ademi Z
    Endocr Pract; 2022 Jan; 28(1):16-24. PubMed ID: 34389513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
    Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
    Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
    Ong SC; Low JZ; Linden S
    Front Pharmacol; 2023; 14():1195124. PubMed ID: 37342587
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
    Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.